Effect of direct acting anti-viral drugs on myostatin level among CRF Egyptian patients with chronic HCV infection and its correlation with sarcopenia

Abstract

Chronic kidney disease (CKD) is a progressive condition that might negatively affect musculoskeletal health. Secondary sarcopenia due to chronic kidney disease may be accompanied with elevated fall risk and mobility limitations. The loss of muscle mass, in addition to the impact of poor body composition on muscle strength and mobility status are necessary for classification and staging of sarcopenia. Patients with Chronic kidney disease are prone to muscle wasting. Thus, it is important to investigate suitable methods for the clinical assessment of muscle mass. The hemodialysis was found to stimulate protein degradation and reduced protein synthesis for 2hr following dialysis, suggested that a process causing protein loss was initiated by this therapy and persisted. Increasing the intake of protein and calories could improve protein turnover but, it did not fully correct the responses to hemodialysis. Patients with chronic kidney disease are subjected to muscle wasting. So, it was important to investigate surrogate methods that enable the assessment of muscle mass loss in the clinical setting. Myostatin is the major negative regulator of growth that is highly enriched in skeletal muscle. There was great interest in myostatin as a potential mediator of sarcopenia as well as a therapeutic target. The recent advent of interferon-free direct-acting antiviral (DAA) represents a marked change in therapy against hepatitis C virus (HCV), and excellent sustained virologic response (SVR) rates have been demonstrated.